Connective Tissue Diseases

 Screens

Products

Article No.

No. of tests

Varelisa ReCombi ANA Screen 125 96 96 tests

Varelisa ANA 8 Screen -
not for sale in the U.S.

124 96 96 tests
EliA Symphony Well 14-5508-01 4x12 tests

EliA CTD Screen - 
not for sale in the U.S.

14-5596-01 4x12 tests

 

Promotion Material

Performance Folder
EliA ANA Differentiation
Sm, U1RNP, RNP70, RO, La, Scl-70, CENP, Jo-1

Antigens

Antinuclear antibodies bind intracellular antigens and are serological hallmarks of systemic rheumatic diseases. In contrast to indirect immunofluorescence assays ELISAs do not screen the whole range of antinuclear antibodies but only those, which are known to be specific for connective tissue diseases.

Antigens in the Varelisa ReCombi ANA Screen:

dsDNA (recombinant plasmid double-stranded DNA)
U1-snRNP (human recombinant)
Sm (B, B', D)

(complex purified from human HeLa cells)

SS-A/Ro

(complex purified from human HeLa cells)

SS-B/La

(human recombinant)

Scl-70 (human recombinant topoisomerase 1)
CENP (human recombinant CENP-B)
Jo-1 (human recombinant histidylt RNA synthetase)

 

Antigens in the Varelisa ANA 8 Screen:

U1-snRNP (human recombinant)
RNP-Sm (complex purified from human HeLa cells)
Sm (B, B', D)

(complex purified from human HeLa cells)

SS-A/Ro (human recombinant 52 kD and 60 kD)
SS-B/La

(human recombinant)

Scl-70 (human recombinant topoisomerase 1)
CENP (human recombinant CENP-B)
Jo-1 (human recombinant histidylt RNA synthetase)

 

Antigens in the EliA Symphony:

U1-snRNP (human recombinant U1 70 kD, A and C)
Sm (purified from human HeLa cells)
SS-A/Ro (human recombinant 52 kD and 60 kD)
SS-B/La

(human recombinant)

Scl-70 (human recombinant topoisomerase 1)
CENP (human recombinant CENP-B)
Jo-1 (human recombinant histidylt RNA synthetase)

 

Antigens in the EliA CTD Screen:

U1RNP (human recombinant (RNP70, A, C))
SS-A/Ro (human recombinant (60 kDa, 52 kDa))

SS-B/La

(human recombinant)
centromere B

(human recombinant)

Scl-70 (human recombinant)
Jo-1 (human recombinant)
fibrillarin (human recombinant)
RNA Pol III (human recombinant)
Rib-P (human recombinant)
PM-Scl (human recombinant)
PCNA (human recombinant)
Mi-2 proteins (human recombinant)
Sm proteins (human recombinant)
DNA (native purified)

 

Disease association, antibody prevalence and specificity

Autoantigen

Disease and Prevalence

Clinical Significance

dsDNA

SLE: 60 - 90 % Specific marker in SLE, dsDNA antibodies correlate with disease activity (monitoring), marker for tissue damage dsDNA antibodies are associated with an increased risk of nephritis, specificity is 95%.
RNP
(70 kDa, A, C)
SLE: 30 - 70 %
MCTD: 100 %
U1 snRNP antibodies indicate a good prognosis concerning the development of renal involvement, also when they are found in combination with Sm.
MCTD is defined through high levels of anti-U1 snRNP.
Sm
(B, B', D)
SLE: 10 - 30 % Specific marker for SLE (specificity 99%)
SS-A/Ro
(52 kD, 60 kD)
SLE: 25 - 50 %
SS: 60 - 90 %
Neonatal Lupus: > 95 %
High risk of neonatal lupus if mother has SS-A/Ro (especially when directed to 52 kD) and SS-B/La antibodies
SS-B/La SLE: 5 - 15 %
SS: 40 - 95 %
Neonatal Lupus
SS-B/La antibodies are found almost always in combination with anti-SSA antibodies; more specific for Sjögren¿s syndrome than Anti-SS-A/Ro
Scl-70 Scleroderma:
20 - 70 %
Specific marker for scleroderma (specificity 98-100 %)
Centromere
(CENP-B)
CREST: 50 % (other sources: 40 - 90 %)
Raynaud's disease: 10 - 15 %
Present in patients with limited form of scleroderma
Jo-1 Poly-/Dermatomyositis: 30 % Patients often have lung involvement. Jo-1 antibodies positive patients tend to have a severe disease with poor response to therapy

Disease activity

Single antigens in the profile have good correlation with the disease activity, others not. For monitoring the measurement of single specificities is recommended.

When is the measurement recommended?

Suspicion of Connective Tissue Disease.

Antibody isotypes

IgG

References

J.B. Peter, Y. Shoenfeld (1996)  |  Venrooij WJ, Maini RN (1996)  |  Peene I, Meheus L, Veys EM, De Keyser F (2001)  |  Peng SL, Hardin JA, Craft J (1997)

Back to top

 

As in all diagnostic testing, the diagnosis is made by the physican based on both test results and the patient history.